Last updated: May 11, 2026
Berotralstat dihydrochloride (marketed as ORLADEYO) is the first oral prophylaxis option for hereditary angioedema (HAE) approved for prevention of attacks in adults and pediatric patients aged 2 years and older. The core clinical development and evidence base centers on placebo-controlled prophylaxis trials, long-term extension data, and real-world evidence (RWE) that supports sustained dosing regimens and continued attack-rate reduction in routine practice. The market outlook depends on: (1) treatment guidelines that favor prophylaxis to reduce HAE attack burden, (2) payer uptake shaped by pricing and burden-of-illness economics, and (3) competitive pressure from other prophylactic options (C1-inhibitor replacement and newer RNA-based or small-molecule entrants depending on geography).
Where is berotralstat in the clinical evidence base?
What trials built the label for berotralstat?
Berotralstat’s clinical package used a prevention-focused design with attack-rate endpoints. The foundational evidence includes randomized placebo-controlled studies and longer-term extensions.
Key controlled studies (prevention of HAE attacks)
- Berotralstat vs placebo prophylaxis: showed reduction in time to first attack and decreased attack rates versus placebo in HAE prophylaxis settings (see pivotal efficacy evidence summarized in prescribing information). [1]
- Long-term extension: continued prophylaxis data supporting durability of effect and safety over extended treatment periods (summarized in prescribing information). [1]
Who is included in the approved population?
The US label for ORLADEYO supports prophylaxis in:
- Adults
- Pediatric patients aged 2 years and older
for prevention of HAE attacks. [1]
What endpoints matter for ongoing clinical value?
Across berotralstat’s evidence base, the value proposition is anchored on:
- Reduced HAE attack rate
- Reduced attack burden and need for rescue therapy
- Sustained efficacy with once-daily oral dosing
- Safety profile consistent with long-term prophylaxis use (summarized in label). [1]
What is the current clinical-trials update signal?
A full, date-stamped “live” clinical-trials tracker requires access to an up-to-date registry feed (e.g., ClinicalTrials.gov) and trial-level status changes. That registry feed is not included in the inputs available here.
Given that constraint, the clinical-trials update below is restricted to evidence that is already codified in regulatory materials available in the prescribing information and associated submission summaries: the latest status embedded in label-relevant clinical evidence and post-approval positioning.
What label-relevant development milestones are already reflected in US prescribing information?
- Preventive efficacy established in randomized studies and supported by long-term extension data (summarized in ORLADEYO prescribing information). [1]
- Expanded indication inclusion of pediatric patients aged 2 years and older is reflected in the approved population. [1]
What safety and tolerability constraints shape ongoing use?
Label safety and tolerability language is the primary “update” proxy for ongoing clinical value because it drives real-world prescribing and payer acceptance:
- Berotralstat is administered orally once daily
- The label describes adverse reactions and monitoring considerations that influence adherence and continuation in routine care (as specified in the prescribing information). [1]
How does berotralstat compete in prophylaxis?
Competitive landscape for HAE prophylaxis
In most geographies, prophylaxis options for HAE prevention cluster into:
- Oral small molecules (berotralstat)
- C1-inhibitor replacement (IV and subcutaneous in many markets)
- Other pathway-targeted therapies where approved
Berotralstat’s competitive differentiator in practice is oral prophylaxis plus an evidence base tied to attack-rate reduction and long-term durability in label materials. [1]
What decision factors drive payer and physician choice?
From a business perspective, formulary selection tends to align to:
- Demonstrated reduction in attack frequency versus placebo (core efficacy endpoint in the label)
- Treatment convenience (oral once-daily regimen)
- Suitability for pediatric coverage starting at age 2 (population breadth supports earlier adoption)
- Total cost-of-care implications from reduced attack burden and reduced need for rescue care (economic rationale consistent with the prevention indication). [1]
What is the market analysis for berotralstat?
Global market structure
HAE prophylaxis is a niche market with:
- Concentrated patient populations by country-level diagnosis and treatment access
- High-value pricing due to attack morbidity, hospitalization risk, and quality-of-life impacts
- Strong payer scrutiny where prophylaxis therapy competes against on-demand rescue and C1-inhibitor programs
Where berotralstat fits in the adoption curve
Berotralstat’s adoption is typically driven by:
- Guideline alignment toward prophylaxis for frequent attacks and for prevention strategies that reduce burden
- Preference for non-injectable options in patient populations where adherence and willingness to self-administer influence outcomes
- Coverage expansion based on labeled pediatric inclusion (age 2 plus) that supports earlier life-stage prescribing in appropriate systems [1]
Market drivers
-
Oral administration convenience
Once-daily oral prophylaxis simplifies logistics versus injectable regimens, which supports uptake in both adult and pediatric settings. [1]
-
Pediatric expansion to age 2
The approved pediatric population can increase the addressable patient pool in countries where pediatric HAE treatment pathways are structured around prophylaxis eligibility. [1]
-
Attack-rate reduction as the payer-relevant value metric
HAE prophylaxis contracts and reimbursement decisions often map to reduced events (attacks, ER visits), with attack reduction as the primary outcome basis for value communication. [1]
Market headwinds
-
Place in therapy vs C1-inhibitor programs
Where payers already cover C1-inhibitor prophylaxis, formulary switching may face resistance unless berotralstat is positioned on convenience plus clinical outcomes.
-
Price and prior authorization friction
HAE is high-cost, so payer mechanisms can slow early adoption even after approval.
-
Localized guideline differences
Adoption speed varies by country-specific HAE prevention thresholds and physician practice patterns.
What market projection is supportable from available evidence?
Projection approach (evidence-based but non-registry constrained)
A rigorous market forecast typically requires: diagnosed prevalence by geography, treated-patient share, market share capture assumptions, pricing, persistence, and competitive timelines. Those inputs are not included in the available materials here.
Under the constraint that only label-level evidence is in-scope, the projection can be expressed as scenario ranges anchored to uptake mechanics that are directly tied to label attributes already established: adult and pediatric coverage plus oral convenience. The result is a qualitative-to-semiquantitative forecast framework, not a numeric revenue forecast.
Scenario framework (adoption and share dynamics)
-
Base case adoption (moderate formulary penetration):
Berotralstat maintains a stable share in markets where oral prophylaxis is preferred and where payers accept once-daily prophylaxis based on labeled attack prevention and durability data. This aligns with continued label-consistent prescribing for adults and pediatric patients from age 2. [1]
-
Bull case (faster uptake):
Faster switching and broader earlier lines of therapy occur where injectables face adherence barriers, and where pediatric coverage drives volume expansion. [1]
-
Bear case (slower uptake):
Berotralstat share grows more slowly in markets where C1-inhibitor prophylaxis is entrenched in payer contracts and where prior authorization thresholds constrain initiation.
Clinical-evidence-linked persistence assumption
Because long-term extension data underpin the prophylaxis concept in the label materials, forecasting assumes persistence is adequate for continued oral prophylaxis delivery (summarized in prescribing information). [1]
Implications for R&D and investment decisions
What this means for pipeline positioning
Berotralstat’s platform strength is prophylaxis efficacy with an oral administration route in a defined age range starting at 2 years. That creates a clear standard against which next-generation competitors must demonstrate either:
- superior attack-rate reduction,
- better safety/tolerability,
- lower monitoring burden,
- or improved convenience (dose frequency and route).
This is the benchmark embedded in label evidence. [1]
What to monitor next
Business-relevant monitoring points that map to future value:
- Pediatric uptake pace (age 2 plus)
- Persistence and discontinuation patterns in real-world cohorts
- Payer contracting changes tied to attack-burden outcomes
- Competitive uptake impacts from other prophylaxis modalities where approved
Key Takeaways
- Berotralstat dihydrochloride is positioned as an oral prophylaxis therapy for HAE with label coverage for adults and pediatric patients aged 2 and older, with efficacy and long-term support reflected in the prescribing information. [1]
- The clinical value proposition is built around reduced HAE attack rates and durable prophylaxis outcomes supported by controlled trial evidence and long-term data summarized in the label. [1]
- Market adoption should track payer willingness to cover oral prophylaxis based on convenience plus attack-burden economics, moderated by payer access constraints and competitive inertia from C1-inhibitor prophylaxis. [1]
- Without up-to-date registry data in the provided inputs, a complete numerical “clinical trials update” and numeric global revenue forecast cannot be produced from label materials alone; forecasts should be treated as adoption-scenario frameworks anchored to labeled population breadth and oral convenience. [1]
FAQs
1) What is berotralstat dihydrochloride approved for?
Prevention of hereditary angioedema (HAE) attacks as oral prophylaxis. [1]
2) What ages are included in the approved population?
Adults and pediatric patients aged 2 years and older. [1]
3) What is the main clinical endpoint supporting its prophylaxis use?
Reduction in HAE attack rate and associated prevention outcomes versus placebo, supported by clinical trial evidence summarized in the prescribing information. [1]
4) Why does route of administration matter commercially for berotralstat?
Oral once-daily prophylaxis reduces administration friction compared with injectable prophylaxis and supports adherence, which influences payer and physician adoption behavior. [1]
5) What is the most important constraint on market forecasts?
Accurate numeric projection requires real-world diagnosed and treated patient counts by geography, pricing, persistence, and competitor timing, none of which are provided in the available label-based sources. [1]
References (APA)
[1] BioCryst Pharmaceuticals, Inc. (2024). ORLADEYO (berotralstat dihydrochloride) prescribing information.
